This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ampio's Failed Drug Partner Talks Forces Spin-Out Plan

Ampio Pharmaceuticals'  (AMPE) plan to cast off its premature ejaculation and erectile dysfunction drugs into a separate publicly traded company is a nice bit of spin necessitated by the failure to find a partner for the drugs or start late-stage clinical trials by year's end, as previously promised. 

The new standalone company, Viryx Pharmaceuticals, will be tasked with developing Zertane and Zertane ED, Ampio announced Friday. Zertane is a mint-flavored tablet formulation of the old and generic painkiller tramadol. An initial public offering of Viryx shares will be attempted, with Ampio retaining 50-80% ownership stake.

Ampio CEO Michael Macaluso:

The spin off and subsequent funding, if completed, would give both Ampio and Vyrix greater flexibility to focus on and pursue their respective development strategies while potentially providing shareholders with greater value over the longer term.

Yet for most of the last two years, pursuing the approval of Zertane and finding a partner were Ampio's stated goals. Phase III studies required for U.S. approval were supposed to start by the end of 2012. Ampio missed that deadline.  Management's promises to find a partner for Zertane this year have also gone unfulfilled.

Friday's announcement was short on details about how, exactly, Ampio was going to accomplish the Viryx public offering. The new company has a CEO, Jarret Disbrow, the former CEO of Arbor Pharmaceuticals, but little else. A registration statement for the proposed Viryxa IPO has not been filed with the SEC.

Ampio said the process could take up to a year to complete and the company doesn't intend to provide investors with regular updates. Of course, this means the start of the required Zertane clinical trials is being delayed even further. 

Why investors would be interested in owning newly minted Viryx shares also isn't clear. Zertane is not unique.  It's a new use for the old and generic (i.e. cheap and widely available) painkiller tramadol, formulated into a mint-flavored tablet that dissolves quickly in the mouth. Ampio claims the safest and most efficacious dosages of Zertane for premature ejaculation are 62 mg and 89 mg. Rather random-sounding dosing, except when you understand that standard tramadol can be easily prescribed at a 50 mg dose. Few doctors are going to prescribe Zertane at a higher cost when regular tramadol is already available and much cheaper.

Investors have had a healthy appetite for biotech and drug IPOs this year, although not much lately. Several recent IPOs have been cancelled due to lack of investor interest. 

Last month, Oculus Innovative Sciences  (OCLS) failed to spin off its prescription-grade diluted bleach product into a new public company called Ruthigen. Ampio's Viryx sounds a lot like Ruthigen.

Ampio shares closed Friday at $6.74.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs